scispace - formally typeset
J

Junsang Moon

Researcher at Massachusetts Institute of Technology

Publications -  11
Citations -  336

Junsang Moon is an academic researcher from Massachusetts Institute of Technology. The author has contributed to research in topics: Corticosterone & Catalysis. The author has an hindex of 5, co-authored 9 publications receiving 198 citations. Previous affiliations of Junsang Moon include Seoul National University & McGovern Institute for Brain Research.

Papers
More filters
Journal ArticleDOI

N-doped graphene quantum sheets on silicon nanowire photocathodes for hydrogen production

TL;DR: In this article, the authors suggest using graphene quantum sheets as a catalyst for the solar-driven hydrogen evolution reaction on Si nanowire photocathodes, and demonstrate that the optimum nanostructures of the Si photocathode exhibit an enhanced photocurrent and a lower overpotential compared to those of a planar Si surface.
Journal ArticleDOI

Remotely controlled chemomagnetic modulation of targeted neural circuits.

TL;DR: A remotely controlled chemomagnetic modulation—a nanomaterials-based technique that permits the pharmacological interrogation of targeted neural populations in freely moving subjects and activates endogenous circuits by enabling the regulated release of receptor ligands.
Journal ArticleDOI

Transgene-free remote magnetothermal regulation of adrenal hormones

TL;DR: This work demonstrates an alternative strategy for modulating peripheral organ function, which relies on the endogenous expression of a heat-sensitive cation channel, transient receptor potential vanilloid family member 1 (TRPV1), and heat dissipation by magnetic nanoparticles (MNPs) in remotely applied alternating magnetic fields to wirelessly control adrenal hormone secretion in genetically intact rats.
Journal ArticleDOI

Magnetothermal nanoparticle technology alleviates parkinsonian-like symptoms in mice.

TL;DR: In this article, a wireless magnetothermal approach to DBS (mDBS) was demonstrated to provide similar therapeutic benefits in two mouse models of Parkinson's disease, the bilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and in the unilateral 6-hydroxydopamine (6-OHDA) model.